Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population

Pain

Volumn 141, Issue 1-2, 2009, Pages 14-18

  Brefel Courbon, Christine ^a,b,c   Grolleau, Sabrina ^c   Thalamas, Claire ^b   Bourrel, Robert ^d   Allaria Lapierre, Valérie ^d   Loï, Robert ^d   Micallef Roll, Joelle ^e   Lapeyre Mestre, Maryse ^a,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^e TIMONE HOSPITAL   (France)

Author keywords

Analgesic drugs; Chronic pain; Parkinson's disease; Prevalence

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDIABETIC AGENT; ANTIPARKINSON AGENT; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; GABAPENTIN; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TRAMADOL;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; FRANCE; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHIC PAIN; OSTEOARTHRITIS; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; CHRONIC DISEASE; DIABETES MELLITUS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PARKINSON DISEASE; POPULATION GROUPS; POPULATION SURVEILLANCE;

EID: 58149170456     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2008.04.026     Document Type: Article

References (36)

1. Blyth F.M., March L.M., Brnabic A.J., Jorm L.R., Williamson M., and Cousins M.J. Chronic pain in Australia: a prevalence study. Pain 89 (2001) 127-134
2. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2007. Available at: doi:10.1016/j.pain.2007.08.013.
3. Brandt-Christensen M., Kvist K., Nilsson F.M., Andersen P.K., and Kessing L.V. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 21 (2006) 1221-1225
4. Brandt-Christensen M., Lopez A.G., Nilsson F.M., Andersen P.K., and Kessing L.V. Depressive disorders and anti-parkinson drug treatment: a case register study. Acta Psychiatr Scand 115 (2007) 466-472
5. Brefel-Courbon C., Payoux P., Thalamas C., Ory F., Quelven I., Chollet F., et al. Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20 (2005) 1557-1563
6. Catala E., Reig E., Artes M., Aliaga L., Lopez J.S., and Segu J.L. Prevalence of pain in the Spanish population: telephone survey in 5000 homes. Eur J Pain 6 (2002) 133-140
7. Chan A.W., MacFarlane I.A., Bowsher D.R., Wells J.C., Bessex C., and Griffiths K. Chronic pain in patients with diabetes mellitus: comparison with a non-diabetic population. Pain Clinic 3 (1990) 147-159
8. Chiò A., Magnani C., and Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 13 (1998) 400-405
9. Chopra A., Saluja M., Patil J., and Tandale H.S. Pain and disability, perceptions and beliefs of a rural Indian population: A WHO-ILAR COPCORD study. WHO-international league of associations for rheumatology. community oriented program for control of rheumatic diseases. J Rheumatol 29 (2002) 614-621
10. Chudler E.H., and Dong W.K. The role of the basal ganglia in nociception and pain. Pain 60 (1995) 3-38
11. Clark J.A., Spiro III A., Fincke G., Miller D.R., and Kazis L.E. Symptom severity of osteoarthritis of the knee: a patient-based measure developed in the Veterans health study. J Gerontol A Biol Sci Med Sci 53 (1998) M351-M360
12. Djaldetti R., Shifrin A., Rogowski Z., Sprecher E., Melamed E., and Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 62 (2004) 2171-2175
13. Duarte-Ramos F., and Cabrita J. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal. Pharmacoepidemiol Drug Safety 15 (2006) 269-274
14. Elliott A.M., Smith B.H., Penny K.I., Smith W.C., and Chambers W.A. The epidemiology of chronic pain in the community. Lancet 354 (1999) 1248-1252
15. Ford B. Pain in Parkinson's disease. Clin Neurosci 5 (1998) 63-72
16. Gerdelat-Mas A., Simonetta-Moreau M., Thalamas C., Ory-Magne F., Slaoui T., Rascol O., and Brefel-Courbon C. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 78 (2007) 1140-1142
17. Giuffrida R., Vingerhoets F.J., Bogousslavsky J., and Ghika J. Pain in Parkinson's disease. Rev Neurol 161 (2005) 407-418
18. Goetz C.G., Tanner C.M., Levy M., Wilson R.S., and Garron D.C. Pain in parkinson's disease. Mov Disord 1 (1986) 45-49
19. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atcddd/ [accessed December 2006].
20. Gureje O., Von Korff M., Simon G.E., and Gater R. Persistent pain and well-being: a WHO study in primary care. JAMA 280 (1998) 147-151
21. International Association for the Study of Pain. Classification of chronic pain. Pain 1986;3:S1-226.
22. Koller W.C. Sensory symptoms in Parkinson's disease. Neurology 34 (1984) 957-959
23. Krein S.L., Heisler M., Piette J.D., Makki F., and Kerr E.A. The effect of chronic pain on diabetes patients' self-management. Diabetes Care 28 (2005) 65-70
24. Lajugie D., Bertin N., Chantelou M.L., Vallier N., Weill A., Fender P., et al. The prevalence of Parkinson's disease and its cost to the French national health fund in metropolitan France in 2000. Rev Med Ass Maladie 36 (2005) 113-122
25. Latham J., and Davis B.D. The socioeconomic impact of chronic pain. Disabil Rehabil 16 (1994) 39-44
26. Lee M.A., Walker R.W., Hildreth T.J., and Prentice W.M. A survey of pain in idiopathic Parkinson's disease. J Pain Symptom Manage 32 (2006) 462-469
27. Maggini M., Salmaso S., Alegiani S.S., Caffari B., and Raschetti R. Epidemiological use of drug prescriptions as markers of disease frequency: an Italian experience. J Clin Epidemiol 44 (1991) 1299-1307
28. Montagnier D., Barberger-Gateau P., Jacqmin-Gadda H., Dartigues J.F., Rainfray M., Peres K., et al. Evolution of prevalence of depressive symptoms and antidepressant use between 1988 and 1999 in a large sample of older French people: results from the Personnes Agees Quid study. J Am Geriatr Soc 54 (2006) 1839-1845
29. Papoz L. Utilization of drug sales data for the epidemiology of chronic diseases: the example of diabetes. The EURODIAB Subarea C Study Group. Epidemiology 4 (1993) 421-427
30. Rochat P., Hallas J., Gaist D., and Friis M.L. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand 104 (2001) 6-11
31. Sindrup H.J., and Jensen T.S. Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
32. Snider S.R., Fahn S., Isgreen W.P., and Cote L.J. Primary sensory symptoms in parkinsonism. Neurology 26 (1976) 423-429
33. Tolosa E., Wenning G., and Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 5 (2006) 75-86
34. Ubeda A., Cardo E., Selles N., Broseta R., Trillo J.L., and Fernandez-Llimos F. Antidepressant utilization in primary care in a Spanish region: Impact of generic and reference-based pricing policy (2000-2004). Soc Psychiatry Psychiatr Epidemiol 42 (2007) 181-188
35. Van de Vijver D.A., Roos R.A., Jansen P.A., Porsius A.J., and de Boer A. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Safety 10 (2001) 549-554
36. Verhaak P.F., Kerssens J.J., Dekker J., Sorbi M.J., and Bensing J.M. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 77 (1998) 231-239